Insider Selling: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells 51,043 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) COO Douglas F. Kling sold 51,043 shares of the business's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $21.10, for a total value of $1,077,007.30. Following the completion of the sale, the chief operating officer owned 44,000 shares in the company, valued at approximately $928,400. The trade was a 53.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS traded up $0.22 on Monday, hitting $22.42. The company's stock had a trading volume of 390,761 shares, compared to its average volume of 745,554. The company has a market capitalization of $2.52 billion, a PE ratio of -11.87 and a beta of -0.03. The company has a 50-day simple moving average of $19.35 and a 200 day simple moving average of $20.14. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative net margin of 397.45% and a negative return on equity of 37.34%. The company had revenue of $2.98 million during the quarter, compared to analysts' expectations of $1.46 million. On average, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on NAMS. Needham & Company LLC reaffirmed a "buy" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. The Goldman Sachs Group assumed coverage on shares of NewAmsterdam Pharma in a research report on Thursday. They issued a "neutral" rating and a $27.00 price target on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 target price on the stock. Finally, Citigroup began coverage on NewAmsterdam Pharma in a research report on Tuesday, June 17th. They set a "buy" rating and a $42.00 target price on the stock. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, NewAmsterdam Pharma presently has a consensus rating of "Moderate Buy" and an average target price of $41.30.

Institutional Trading of NewAmsterdam Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Deerfield Management Company L.P. Series C grew its position in NewAmsterdam Pharma by 378.4% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock valued at $110,879,000 after acquiring an additional 3,412,590 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in NewAmsterdam Pharma by 23.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock worth $409,052,000 after purchasing an additional 3,061,224 shares during the period. Wellington Management Group LLP lifted its stake in NewAmsterdam Pharma by 2,410.4% in the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after purchasing an additional 2,222,900 shares during the last quarter. Capital International Investors purchased a new stake in NewAmsterdam Pharma during the fourth quarter valued at about $53,007,000. Finally, Alliancebernstein L.P. purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $47,752,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.